Natco Pharma has acquired the remaining 49% stake in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. This acquisition gives Natco Pharma, through its wholly-owned subsidiary (WOS), 100% ownership of PT NATCO Lotus Farma. The turnover for PT NATCO Lotus Farma was IDR 5,073 million (~₹2.7 crores) YTD Sep 2025.
Acquisition Overview
Natco Pharma Asia Pte. Ltd., a wholly-owned subsidiary (“WOS”) of Natco Pharma Limited (“NATCO”), has acquired the remaining 49% shareholding in PT NATCO Lotus Farma.
Complete Ownership
Prior to this transaction, Natco already held 51% of PT NATCO Lotus Farma. Following the acquisition, Natco, along with its WOS, now wholly-owns 100% of PT NATCO Lotus Farma.
Target Company Details
The target entity is PT NATCO Lotus Farma, an Indonesian subsidiary.
Financial Details
Turnover of PT NATCO Lotus Farma for the last three periods is as follows:
- YTD Sep 2025: IDR 5,073 million (~₹2.7 crores)
- April – March 2025: IDR 3,324 million (~₹1.6 crores)
- April – March 2024: NIL
- April – March 2023: NIL
Consideration
The nature of consideration for the acquisition was cash.
Cost
The cost of acquisition is IDR 14,075,400,000 (~₹7.7 crores) at par/nominal per share value of IDR 100,000.
Line of Business
The acquired entity’s line of business is pharmaceuticals.
Date of Incorporation
PT NATCO Lotus Farma was incorporated on August 28, 2023.
Presence
The acquired entity has a presence in Indonesia.
Source: BSE
